Cytori Therapeutics, Inc recently received a Notice of Allowance from the US Patent and Trademark Office related to uses of the Celution System for the treatment of bone related disorders. Specifically, the allowed claims cover prosthetic devices that can be seeded with adipose derived stem and regenerative cells for use in bone healing and regeneration.

In addition, the company received a second Notice of Allowance related to methods of obtaining clinically safe outputs from the Celution System. The allowed claims cover methods of testing the Celution output for contaminants such as red blood cells, lipids, enzymes, aggregates, and endotoxins, among other things.

Cytori's intellectual property portfolio currently includes 14 issued US and international patents including US Patent No 7,514,075 (the '075 patent), which was recently issued on April 7, 2009. With more than 40 issued claims, the '075 patent expands protection for the Celution System. Key patent claims cover multiple reagents and additives that are critical for optimizing intravascular delivery of the Celution System output for indications such as cardiovascular disease, liver disease and renal failure.

Cytori develops and globally commercializes regenerative medicine technologies, which provide real-time, point-of-care access to clinical grade regenerative cells.